CClinicalTrials.gg
Active, not recruitingNCT04469231Updated Nov 19, 2025

The Synergy Disc To Anterior Cervical Discectomy and Fusion

An interventional study of Anterior Cervical Discectomy & Fusion in Cervical Degenerative Disc Disease, sponsored by Synergy Spine Solutions. Active, not recruiting at 20 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Synergy Spine Solutions · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A multicenter, prospective, non-randomized, historically controlled study. Demonstrate the Synergy Disc is at least as safe and effective as conventional anterior cervical discectomy and fusion (ACDF) to treat cervical degenerative disc disease (DDD) in subjects who are symptomatic at only one level from C3 to C7 that are unresponsive to conservative management. Patients will be evaluated preoperatively, at the time of surgery, and at 6 weeks, 3, 6, 12, and 24 months after surgery. Follow-up will continue annually until the last patient reaches 24-month follow-up. The primary analysis will occur at 24 months.

Read the detailed description

The proposed investigation is a prospective, non-randomized, multi-center, historically controlled comparison of the Synergy Disc to the control of conventional anterior cervical discectomy and fusion (ACDF) surgery in patients with cervical DDD. A total of 175 patients will be enrolled to the investigational group. The investigational group results will be compared to a historical control data from the ACDF control group, which utilized an identical study design. A statistically rigorous observational study design using propensity score (PS) subclassification will be used to demonstrate covariate balance and enhance the quality of inferences regarding effectiveness and safety relative to ACDF control. After investigational device enrollment is complete, but before most investigational device subjects have reached their 24-month endpoint, a data set containing only baseline covariates of prospectively enrolled investigational device patients and historical ACDF control patients will be constructed. The propensity score methods detailed below will be implemented by an outcomes-blinded statistician. A Propensity Score Memo summarizing the proposed observational design will be developed and submitted for review by stakeholders including FDA. The outcomes-blinded statistician will remain blinded until after consensus is achieved that the design is acceptable. This will allow for additional outcomes-blinded PS modeling if required. The objective of this clinical trial is to demonstrate the Synergy Disc is at least as safe and effective as conventional ACDF to treat cervical DDD in subjects who are symptomatic at only one level from C3 to C7 that are unresponsive to conservative management.

02

Conditions studied

  • Cervical Degenerative Disc Disease
03

In context

Lead sponsor

Synergy Spine Solutions is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 18 70 years;
  2. Diagnosis of radiculopathy or myelopathy of the cervical spine, with either radiculopathy symptoms - pain, paresthesia, or paralysis in a specific nerve root distribution C4, C5, C6, or C7, including at least one of the following: arm/shoulder pain (at least 30 mm on 100 mm VAS scale); decreased muscle strength of at least one level on the 0-5 scale described below; abnormal sensation, including hyperesthesia or hypoesthesia; and/or abnormal reflexes; or myelopathy symptoms including positive Romberg evaluation, abnormal heel/toe walk, pathologic hyperreflexia or clonus in lower extremity, positive Babinski, or positive Hoffman's;
  3. Symptomatic at only one level from C3-C4 to C6-C7;
  4. Radiographically determined pathology at level to be treated correlating to primary symptoms, including at least one of the following:

    1. Decreased disc height compared to adjacent levels on radiographic film, CT, or MRI
    2. Degenerative spondylosis on CT or MRI
    3. Disc herniation on CT or MRI.
  5. Neck Disability Index (NDI) score ≥ 30/100;
  6. Unresponsive to non-operative treatment for six weeks, or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment;
  7. Appropriate for treatment using an anterior surgical approach, including having no more than one previous anterior surgical approach to the cervical spine;
  8. Ability and willingness to comply with follow-up regimen; and
  9. Written informed consent given by subject or subject's legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Infection at the site of surgery;
  2. History of, or anticipated treatment for, active systemic infection, including HIV infection or hepatitis C;
  3. Prior attempted or completed cervical spine surgery, except (1) laminoforaminotomy (greater than 6 months prior to scheduled surgical treatment), which includes removal of disc material necessary to perform a nerve root decompression, with less than one-third facetectomy at any level, or (2) a successful single-level anterior cervical fusion (greater than 6 months prior to scheduled surgical treatment);
  4. More than one immobile vertebral level between C1-T1 from any cause, including but not limited to congenital abnormalities, osteoarthritic "spontaneous" fusions, and prior cervical spinal fusions;
  5. Previous trauma to the C3-T1 levels resulting in significant bony or disco-ligamentous cervical spine injury;
  6. Axial neck pain in the absence of other symptoms of radiculopathy or myelopathy justifying the need for surgical intervention;
  7. Radiographic confirmation of severe facet joint disease or degeneration.
  8. Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) for females or MORES (Male Osteoporosis Risk Estimation Score), will be used to screen patients to determine those patients who require a Hip DXA, a bone mineral density measurement. A SCORE or MORES ≥ 6 requires a DXA. If DXA is required, exclusion will be defined as a DXA bone density measured T score ≤ -2.5 (The World Health Organization definition of osteoporosis). DXA scans within the last 6 months prior to surgical treatment may be used;
  9. Paget's disease, osteomalacia, or any other metabolic bone disease (excluding osteoporosis which is addressed above);
  10. Severe diabetes mellitus requiring daily insulin management;
  11. Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years;
  12. Tumor as source of symptoms;
  13. Symptomatic DDD or significant cervical spondylosis at two or more levels;
  14. Marked cervical instability on resting lateral or flexion/extension radiographs demonstrated by:

    1. Translation > 3.5 mm and/or
    2. 11° angular difference to that of either adjacent level;
  15. Known or suspected allergy to cobalt, chromium, molybdenum, titanium, or polyethylene;
  16. Severe myelopathy to the extent that the patient is wheelchair bound;
  17. Congenital canal stenosis resulting in a canal diameter of \< 10 mm, as measured by CT or MRI;
  18. Kyphotic segmental angulation of greater than 11 degrees at treatment or adjacent levels;
  19. Arachnoiditis;
  20. Pregnant (verified in patients of childbearing potential by a negative urine pregnancy test when pre-admission testing is obtained), or interested in becoming pregnant during the duration of the study;
  21. Autoimmune disorders that impact the musculoskeletal system (e.g., lupus, rheumatoid arthritis; ankylosing spondylitis);
  22. Congenital bony and/or spinal cord abnormalities that affect spinal stability;
  23. Spinal axis disease (thoracic or lumbar) to the extent that surgical consideration is likely anticipated within 6 months after the cervical procedure;
  24. Other degenerative joint disease (e.g. shoulder, hip, knee) to the extent that surgical consideration is likely anticipated within 6 months after the cervical procedure;
  25. Diseases or conditions that would preclude accurate clinical evaluation (e.g. neuromuscular disorders such as diffuse idiopathic skeletal hyperostosis (DISH));
  26. Medications that could interfere with fusion or other bone/soft tissue healing (e.g. anticipated continued use of systemic steroid medication postoperatively);
  27. Currently experiencing acute episode of major mental illness (psychosis, major affective disorder, or schizophrenia), or manifesting physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin;
  28. Current or recent history of substance abuse (drug or alcohol) per site PI's determination;
  29. Morbid obesity, defined as body mass index ("BMI") > 40;
  30. Currently using, or planning to use, bone growth stimulators in the cervical spine;
  31. Use of any other investigational drug or medical device within the last 30 days prior to surgery;
  32. Currently a prisoner;
  33. Currently pursuing personal litigation (defined as litigation that will likely influence the patient's ability or willingness to accurately report their treatment outcomes) related to the neck or cervical spine injury; however, involvement in worker's compensation related litigation is not a required exclusion.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Synergy Disc

    The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restoring kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a single level discectomy for intractable radiculopathy and/or myelopathy.

    Device: Anterior Cervical Discectomy & Fusion

Interventions

  • DeviceAnterior Cervical Discectomy & Fusion

    ACDF

    Also known as: ACDF

06

What researchers measure

Primary outcomes

  1. NDI

    ≥ 15-point improvement in NDI Score (out of 100) in subjects at 24 months compared with baseline

    Time frame: 24 Month

  2. Neurological Assessment

    Maintenance or improvement in neurological status (motor and sensory only) at 24 months compared to baseline

    Time frame: 24 Month

  3. SSI

    No study failure due to secondary surgical interventions (revision, removal, re-operation, supplemental fixation) at the index level

    Time frame: 24 Month

  4. Device Related AE

    Absence of major device related adverse events defined as radiographic failure, neurological failure, or failure by adverse event as adjudicated by the CEC.

    Time frame: 24 Month

Secondary outcomes

  1. SF-3

    Health Survey (SF-36) at baseline and at each follow-up time-point

    Time frame: 6 Week, 3, 6, 12, and 24 Month

  2. VAS

    Visual analogue scale (VAS) will be used to evaluate pain where a change of at least 20mm will be considered clinically significant. Neck pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Left and Right arm/shoulder pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Please note, this assessment will include a "Worst" to pool together the left or right arm/shoulder scores with the higher baseline score. VAS Hoarseness on a 100mm scale.

    Time frame: 6 Week, 3, 6, 12, and 24 Month

  3. Patient Satisfaction

    Patient Satisfaction Questionnaire

    Time frame: 6 Week, 3, 6, 12, and 24 Month

  4. BZ Score

    Bazaz Dysphagia Score at 24 months compared to baseline

    Time frame: 6 Week, 3, 6, 12, and 24 Month

  5. Odom's Criteria

    Results at 24 months for the investigational Synergy Disc and at 24 months for the control ACDF will also be categorized by the physician according to Odom's Criteria.

    Time frame: 6 Week, 3, 6, 12, and 24 Month

07

Study locations

20 sites
  • Barrow Brain and Spine
    Phoenix, Arizona 85013, United States
  • HonorHealth Research Institute/Barrow Brain and Spine
    Scottsdale, Arizona 85251, United States
  • Todd H. Lanman, M.D.
    Beverly Hills, California 90210, United States
  • Orthopedic Specialty Institute
    Orange, California 92868, United States
  • Institute of Neuro Innovation
    Santa Monica, California 90404, United States
  • Anschutz Medical Center
    Aurora, Colorado 80045, United States
  • Kennedy White Orthopaedic Center
    Sarasota, Florida 34232, United States
  • Indiana Spine Group
    Carmel, Indiana 46032, United States
  • Michigan Orthopedic Surgeons (2)
    Southfield, Michigan 48033, United States
  • Michigan Orthopedic Surgeons
    Southfield, Michigan 48033, United States
  • Upstate Medical University
    East Syracuse, New York 13057, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Exiamia EquiHealth
    Durham, North Carolina 27704, United States
  • Summit Spine
    Portland, Oregon 97225, United States
  • Center for Sports Medicine and Orthopaedic Surgery (CSMO)
    Chattanooga, Tennessee 37404, United States
  • Central Texas Brain & Spine
    Austin, Texas 78705, United States
  • Austin Neurosurgeons
    Austin, Texas 78746, United States
  • Texas Spine Care Center
    San Antonio, Texas 78231, United States
  • The Disc Replacement Center
    West Jordan, Utah 84088, United States
  • Atlantic Brain & Spine
    Reston, Virginia 20190, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04469231
Lead sponsor
Synergy Spine Solutions
Collaborators
MCRA
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Oct 30, 2020
Primary completion
Jun 19, 2025
Completion
Jan 1, 2026 (estimated)
Last update
Nov 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion